Central Nervous System (CNS)
Acoustic Cluster Therapy (ACT®) increases blood-brain barrier permeability and enhances accumulation of core-crosslinked polymeric micelles
EXACT is currently conducting preclinical studies to demonstrate targeted, temporary, safe opening of the blood-brain barrier
For the next study we will look into delivering PSMA agent with ACT® to glioblastoma in a non-clinical disease model in H1 2024
Further expansion: enabling targeted drug delivery to neurological diseases
ACT can provide targeted, temporary, and safe opening of the blood-brain barrier
The blood-brain barrier
The blood brain barrier (BBB) protects the brain from toxins and pathogens but also impedes the access of most drugs needed to efficiently treat brain diseases.
Targeted delivery to the brain
Only 2% of small molecule drugs and almost no biologic drugs can pass the blood-brain-barrier.
Insufficient drug delivery to the brain leads to low therapeutic efficacy as well as aggravated side effects due to accumulation in other organs.
‘Brain shuffle’ and other molecular delivery technologies provide indiscriminate delivery.
There is a need for non-invasive methods that can provide targeted, temporary, and safe opening of the blood-brain-barrier, for delivery of drugs to specific structures of the brain.
Enhanced blood-brain barrier permeability 1.5-fold
Near infrared fluorescence imaging of excised brains showed a 3.7-fold increase in brain accumulation presented as injected dose per gram brain tissue.
Collaboration partner:
